To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Increased basal ganglia b… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy.

Journal article
Authors Ruben Smith
Martin Schain
Christer Nilsson
Olof Strandberg
Tomas Olsson
Douglas Hägerström
Jonas Jögi
Edilio Borroni
Michael Schöll
Michael Honer
Oskar Hansson
Published in Movement disorders : official journal of the Movement Disorder Society
Volume 32
Issue 1
Pages 108-114
ISSN 1531-8257
Publication year 2017
Published at Institute of Neuroscience and Physiology
Pages 108-114
Language en
Links dx.doi.org/10.1002/mds.26813
www.ncbi.nlm.nih.gov/entrez/query.f...
Subject categories Medical Biotechnology, Clinical Medicine

Abstract

Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work-up of PSP.Regional tau accumulation was studied using (18) F-AV-1451 PET in 11 patients with PSP and 11 age-matched healthy controls in the Swedish BioFinder study.(18) F-AV-1451 standard uptake volume ratios were significantly higher in the basal ganglia in PSP patients when compared with controls (globus pallidus 1.75 vs 1.50; putamen 1.51 vs 1.35). Retention in the basal ganglia was correlated with age in both groups (r = .43-.78, P < .05). In PSP, we observed a significant correlation between clinical deterioration measured with the PSP rating scale and standard uptake volume ratios in the globus pallidus (r = .74, P < .05). However, no (18) F-AV-1451 retention was observed in the cerebral cortex or white matter of either PSP patients or controls, and autoradiography did not reveal any specific binding of AV-1451 to PSP tau aggregates.We found higher (18) F-AV-1451 retention in the basal ganglia of PSP patients when compared with healthy elderly controls, but also increases with age in both controls and patients. As a result of the overlap in retention between diagnostic groups and the age-dependent increase present also in controls, (18) F-AV-1451 PET might not reliably distinguish individual patients with PSP from controls. However, further studies are needed to evaluate whether (18) F-AV-1451 PET might be useful as a progression marker in clinical PSP trials. © The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?